Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up to $1.2 billion.

Reuters reported that Sanofi Pasteur’s general manager, David Loew seemed unconcerned by the potential threat, or commercial opportunity, posed by a potential “universal” flu vaccine ...

As per the “co-exclusive” agreement, Sanofi will also support certain R&D, regulatory, and commercial expenses ... licence to use the vaccine in combination with its flu vaccines, and non ...

The shots include combination jabs targeting Covid and the flu. In a note ... The firm expects Sanofi "to drive greater ...